Maximization of recombinant protein yield in the insect cell/baculovirus system by one-time addition of nutrients to high-density batch cultures

Suspension cultures of Sf-9 cells at different stages of growth were infected with a recombinant baculovirus expressing -galactosidase, using a range of multiplicities of infection (MOI) of 0.05 to 50. Following infection, the cells were resuspended either in the medium in which they had been grown or in fresh medium. Specific -galactosidase yields were not markedly affected by either MOI or medium change in cultures infected in early exponential phase (3×10⁶ cells mL^–1). In cultures infected at later growth stages, -galactosidase yields could only be maintained by medium replacement. The possibility that this requirement for medium replacement is due either to the accumulation of an inhibitory byproduct or nutrient limitation was examined. Alanine, a major byproduct of cultured insect cell metabolism, did not significantly reduce recombinant protein yield when added to infected cultures in concentrations of up to 40 mM. Following a factorial design, various nutrient concentrates were added alone or in combination to cultures infected in late exponential phase. Additions that included both yeastolate ultrafiltrate and an amino acid mixture restored specific -galactosidase yields to levels observed at earlier growth stages or in late stages with medium replacement; the addition of these concentrates, by permitting production at higher cell density, led to increases in the volumetric yield of recombinant protein. Together or separately, the concentrates when added to uninfected late exponential phase cultures, lead to a doubling of the maximum total cell protein level normally supported by unamended medium.     

Overview of a quality assurance/quality control compliance program consistent with FDA regulations and policies for somatic cell and gene therapies: a four year experience

Somatic cell and gene therapy involve the application of biological technologies to an individual patient through the use of living cells which provide a therapeutic benefit (Aliski, 1991). Various forms of cellular and gene therapies are being developed and evaluated in an increasing number of clinical trials for congential and acquired disorders. The potential and progress of these therapeutic applications have resulted in an increasing effort by the Food and Drug Administration (FDA) to develop the regulatory framework under which these therapeutic approaches would insure safety and efficacy, the primary mandate of the FDA.Over five years ago Cellcor began to define the parameters, specifications, and conditions relevant to a Quality Assurance/Quality Control (QA/QC) program that has evolved to insure safety and maximize the efficacy of applications of the company'sex vivo technology, autolymphocyte therapy. Autolymphocyte therapy is an outpatient form of somatic cell immunotherapy based upon the infusion of T cells that have been activatedex vivo using a combination of previously generated autologous cytokines and an anti-CD3 monoclonal antibody.We have been able to demonstrate the feasibility for the safe, controlled, and consistent preparation and delivery of a cellular therapy by application of relevant GMP regulations. This presentation reviews aspects of this program and chronicles our experience which at present amounts to over 4400 infusions for over 700 patients. This program provides a high degree of assurance that a cellular therapy program can be carried out in a multisite mode involving hundreds of patients through the strict adherence to cGMP as set forth in existing regulations. It would be prudent that developers of cellular andex vivo gene therapies establish a similar cell processing and QA/QC infrastructure at an early developmental stage to optimize safety and reproducibility and facilitate regulatory review.     

Nuclear and chloroplast transformation inChlamydomonas reinhardtii: strategies for genetic manipulation and gene expression

Transformation of the nuclear, chloroplast, and mitochondrial genomes can now be accomplished inChlamydomonas reinhardtii. Many biosynthetic pathways are carried out in the chloroplast, and efforts to manipulate these pathways will require that gene products be directed to this compartment. Chloroplast proteins are encoded in either the chloroplast or nuclear genome. In the latter case they are synthesized in the cytoplasm and imported post-translationally into the chloroplast. Thus, strategies for expressing foreign genes or overexpressing endogenous genes whose products reside in the chloroplast could involve either genome. This paper reviews the present status of transformation methodology for the nuclear and chloroplast genomes inChlamydomonas. Considerations for expressing gene products in the chloroplast are discussed. Experimental evidence for homologous recombination during transformation of the nuclear genome is presented.     

A novel isotope labeling protocol for bacterially expressed proteins

Summary A novel protocol for isotopically labeling bacterially expressed proteins is presented. This method circumvents problems related to poor cell growth, commonly associated with the use of minimal labeled media, and problems with protein induction encountered, less commonly, when using enriched labeled media. The method involves initially growing the bacterial cells to high optical density in a commercially available enriched labeled medium. Following a suitable growth period, the cells are transferred to a different (minimal) labeled medium, appropriate for induction. The method is demonstrated using the protein melanoma growth stimulating activity (MGSA).     

胎盘型谷胱甘肽S－转移酶基因在胃癌中的表达

用Ｄｉｇ－ＧＳＴ－πｃＤＮＡ探针分子杂交方法,检测了正常胃组织,胃癌及相应癌旁正常组织中ＧＳＴ－πＤＮＡ和ＧＳＴ－πＲＮＡ水平,发现ＧＳＴ－πＤＮＡ水平没有明显变化,而ＧＳＴ－πＲＮＡ在８例胃癌组织中有６例高于正常胃组织,在１２例低分化腺癌中有７例癌旁正常组织高于相应癌组织,表明ＧＳＴ－π基因表达增加与胃癌有关,而且早于细胞形态的变化。     

Zn2＋参与遗传调控的研究进展

Zn^2＋在遗传调控中的作用十分广泛而显著.结合新近的研究资料,着重从染色质结构与功能、核酸的生物合成、DNA的结构及构象、基因表达的调控等四个主要方面来反映Zn^2＋与遗传调控的相关性,并阐述Zn^2＋在其中发挥作用的机理.     

P53，Rb和c－myc基因在人脑原发性肿瘤中的转录表达

采用RNA斑点杂交分析,对21例人脑原发性胶质瘤和11例人脑膜瘤中p53,Rb和c-myc基因转录水平的表达进行研究.发现48.4%的肿瘤中p53基因表达减弱,21.9%的肿瘤中Rb基因表达减弱;71.9%的肿瘤中c-myc基因表达增强.在p53基因表达减弱的15例病例中有13例(80%)c-myc基因表达增强.结果表明,p53基因表达减弱和c-myc基因表达增强与人脑原发性肿瘤的发生有关.     

高等植物性别分化研究的某些进展

高等植物性别分化研究的某些进展邵宏波（四平师范学院生物工程研究室吉林四平１３６０００）关键词高等植物,性别分化,基因表达ＳＯＭＥＡＤＶＡＮＣＥＳＩＮＴＨＥＳＥＸＵＡＬＤＩＦＦＥＲＥＮＴＩＡＴＩＯＮＲＥＳＥＡＲＣＨＯＦＨＩＧＨＥＲＰＬＡＮＴＳ￥Ｓｈａｏ...     

酶电泳资料和系统与进化植物学研究综述

酶电泳资料和系统与进化植物学研究综述葛颂（中国科学院植物研究所系统与进化植物学开放研究实验室北京１０００９３）关键词同工酶,电泳,植物系统学,进化ＥＬＥＣＴＲＯＰＨＯＲＥＴＩＣＤＡＴＡＡＮＤＳＴＵＤＩＥＳＯＦＰＬＡＮＴＳＹＳＴＥＭＡＴＩＣＳＡＮＤＥＶ...     

γ射线诱发大鼠胚胎细胞转化与N－ras的激活

以γ射线诱发转化的大鼠胚胎细胞(REC:myc:γ33)的DNA构建粘粒基因库,用总基因库DNA转染NIH/3T3细胞,产生转化灶的DNA作二轮转染,二轮转化的NIH/3T3细胞内有大鼠REC:myc:γ33DNA中具转化活性的N-ras基因,用不对称PCR和DNA序列分析法证明,REC:myc:γ33细胞中鼠N-ras的活化是由于第61位密码子的A→G点突变.NIH/3T3转化灶中鼠N-ras也有同样点突变,但NIH/3T3细胞的内源性N-ras基因则无此突变.